You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing a Nutraceutical Product against Noise Induce Hearing Loss
SBC: GATEWAY BIOTECHNOLOGY, INC. Topic: NIDCDPROJECT SUMMARY The most common occupational and environmental hazard in this country is noise Itandapos s not surprising then that noise induced hearing loss NIHL is the second most common form of sensorineural hearing deficit behind only age related hearing loss presbycusis Although therapeutics that target the free radical pathway have shown promise for reducing NIHL there are no effe ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease Using Skin Elasticity as a Biomarker
SBC: Microelastic Ultrasound Systems, Inc. Topic: 102Ultrasound Based Device to Guide Treatment of Graft Versus Host Disease using Skin Elasticity as a Biomarker ABSTRACT Sclerotic chronic graft versus host disease cGVHD develops in of allogenic Human Stem Cell Transplant HCT recipients and is associated with significant morbidity and mortality GVHD is treated with immunosuppression which puts patients at severe risk of infection ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Hernia Mesh to Improve Anchor Point Fixation and Prevent Hernia Formation
SBC: Deep Blue Medical Advances, Inc. Topic: 300Abstract Two million laparotomies are performed annually in the U S with ventral hernia being a frequent complication in of patients The average cost patient for each hernia operation in the U S in was $ which amounts to $ billion annually The ten year ventral hernia recurrence rate is There are $ B in hernia meshes sold annually in the United States With ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a POEGMA Aptamer rapid onset anticoagulant that eliminates antigenicity to anti PEG antibodies
SBC: Gateway Bio, Inc. Topic: NHLBIABSTRACT The objective of this STTR proposal is to reformulate a promising PEG aptamer rapid onset anticoagulant ROA by applying a novel PEG like POEGMA polymer brush technology capable of eliminating anti PEG antigenicity The importance of this proposal is highlighted by the early termination of a recent Phase III clinical trial of the original PEG aptamer conjugate in which severe allergic ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Scaffold to Promote Skin Regeneration
SBC: FirstString Research, Inc Topic: NIAMSPROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Creation of animal models of mitochondrial DNA disease for translational research applications
SBC: ENZERNA BIOSCIENCES LLC Topic: 400Mitochondria are the principal generators of cellular ATP by oxidative phosphorylation which links electron transport via Complexes I through IV to production of ATP via ATP synthase Over pathogenic human mitochondrial DNA mtDNA mutations associated with diseases ranging from cardiomyopathy to juvenile blindness have been identified Collectively millions are affected by mtDNA disease fo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Developing Heparan Sulfate Glycan Array
SBC: GLYCAN THERAPEUTICS CORPORATION Topic: NIGMSProject titleDeveloping heparan sulfate glycan array This proposal is aimed at developing a high throughput method to study the interactions between heparan sulfateHSand proteinsHS is a highly sulfated polysaccharide displaying a wide range of biological functionsGlycan Therapeutics is a company specialized in HS related research productsIn this proposalan HS array technique will be constructed us ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of Fibrin Specific Nuclear Probe to Reduce LVAD Adverse Events
SBC: CAPELLA IMAGING, LLC Topic: NHLBIDespite the myriad major advances in cardiology the prognosis for patients with severe medically refractive heart failure HF is exceedingly poor Approximately deaths occur annually in patients with HF who have endured an impaired quality of life often accompanied by significant economic and personal losses due to recurrent hospitalizations At least of these deaths were directl ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting STT3A and STT3B to Block Flavivirus Replication
SBC: New England Discovery Partners, LLC Topic: NIAIDAbstractMosquito borne flaviviruses cause disease worldwidewith members such as dengue virusDENVZika virusZIKVand west nile virusWNVinfecting more thanmillion individuals annuallyThe availability of small molecule antivirals that reduce flavivirus infection therefore could have an immediate and substantial impact on public health programs that seek to improve outcomes for populations infected with ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
HLS Cyclic CAR peptide a targeted therapy for pulmonary hypertension
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBIPUBLIC ABSTRACT This project in response to announcement HLS describes a development program for CARSKNKDC CAR a synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapies for the treatment of pulmonary hypertension PH PH is a disorder of elevated pulmonary vascular resistance characterized by ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health